Clinical drug trial results and experimental drugs, explained
Spectral Genomics follows experimental medical drugs from early development through clinical trials and FDA review. We explain what clinical trial results actually show, how likely a drug is to succeed, and what to watch next, with every claim linked to its source.
Track drugs. Understand evidence. Evaluate probabilities.
Retatrutide
Eli Lilly and Company · Peptide (once-weekly injection)
Not yet approved
- TRIUMPH-9Active, not recruiting · Oct 2028 (est.)
- TRIUMPH-6Active, not recruiting · Apr 2028 (est.)
- TRIUMPH-7Active, not recruiting · Sep 2027 (est.)
- TRIUMPH-8Active, not recruiting · Jun 2027 (est.)
FDA: not approved (openFDA, checked Nov 19, 2026). Phase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027
Clinical drug trial results: how to read the evidence
A headline that a trial “succeeded” can mean very different things. These guides explain what to check in any clinical drug trial result: the primary endpoint, statistical significance, the control group, and whether the result has been replicated.
What Is a Primary Clinical Trial Endpoint?
A primary endpoint is the main outcome a clinical trial is designed to measure, chosen before the trial starts. Whether it is met usually decides whether the trial counts as a success.
What Is Statistical Significance in Clinical Trials?
A result is statistically significant when it would be unlikely to arise by chance if the drug had no effect, usually judged by a p-value below 0.05. Significance does not tell you how large or important the effect is.
What Is a Placebo-Controlled Trial?
In a placebo-controlled trial, one group receives the experimental drug and another receives an inactive look-alike, usually without anyone knowing who got which. It is the clearest way to show that a drug, and not something else, caused an effect.
What Is an Independent Clinical Trial Replication?
A replication is a separate trial that tests the same question and finds a consistent result. Independent replication is one of the strongest protections against results that turn out to be flukes.
Why Do Phase 3 Clinical Trials Fail?
Roughly 4 in 10 Phase 3 programs fail to reach a marketing application. Most fail because the drug's benefit doesn't hold up in a larger, more rigorous trial, often because the Phase 2 result was overstated.
How Do Scientists Evaluate Drug Safety?
Drug safety is assessed in stages, from animal toxicology to clinical trials to monitoring after approval. Because trials are limited in size, rare side effects are often found only once a drug is widely used.
Open the clinical drug trial tracker: upcoming readouts, stopped trials, and every trial behind our drug profiles.
Experimental medical drugs, from discovery to approval
Most experimental drugs never reach patients. Here is how they are discovered, tested in clinical trials, and reviewed by the FDA, and what the historical odds look like at each stage.
Historical averages for 2011–2020 from BIO, Informa Pharma Intelligence, and QLS Advisors (2021). Approval figures are from the report’s likelihood-of-approval table; the 10.5 years is its average duration. They are not predictions for any individual drug.
How Are New Drugs Discovered?
Drug discovery runs from choosing a biological target, through finding and refining a molecule that acts on it, to the preclinical studies needed before testing in people.
What Are the Phases of Clinical Trials?
Clinical trials move through Phase 1, 2, and 3 before approval, and Phase 4 after it. Each phase asks a different question with a different number of participants.
How Does the FDA Approve New Drugs?
The FDA approves a new drug when the sponsor's application shows substantial evidence that it works and that its benefits outweigh its risks for the intended use. Here is how the review works.
Why Do Experimental Drugs Fail?
About 90% of drugs that enter clinical trials are never approved. Most fail because they do not work well enough in patients or because their side effects are unacceptable.
What Percentage of Phase 2 Drugs Get Approved?
Roughly 15% of drugs in Phase 2 go on to FDA approval, based on industry data from 2011 to 2020. The odds range from about 10% to more than 30% depending on the disease area and whether patients are selected with biomarkers.
How Are Drug Approval Probabilities Calculated?
Drug approval probabilities are usually built from historical phase transition rates, multiplied together. How programs are counted changes the answer, and estimates for individual drugs require models that account for the evidence.
Drug pipeline tracking
A drug’s prospects change with every trial readout and regulatory decision. Spectral Genomics tracks experimental drugs and the companies developing them, linked to ClinicalTrials.gov, FDA records, SEC filings, and company press releases.
Drug profiles re-check trial records against ClinicalTrials.gov and FDA status against openFDA, company pipeline pages show each sponsor’s active trials by phase, and Pipeline News collects company disclosures about the drugs we track. Every milestone carries its date, its source, and a label showing whether it was company-reported.
Milestones we track
- A clinical trial reports results
- A primary endpoint is met or missed
- A trial is suspended or terminated
- A drug advances to another development phase
- The FDA grants a regulatory designation
- An approval or Complete Response Letter is announced
Biotech drug intelligence in four layers
Drug Intelligence
Profiles of experimental drugs: mechanism, indications, development stage, and what the evidence says about their prospects.
Clinical Intelligence
Clinical trial results, endpoints, safety findings, and historical success rates by phase and disease area.
Company Intelligence
Drug pipeline tracking for sponsors: milestones, partnerships, and what companies disclose in their filings.
Scientific Knowledge
Sourced explainers on drug development, clinical evidence, genomics, and biotechnology.
The genomics behind new drugs
Drug targets backed by human genetic evidence have been about 2.6 times more likely to succeed. These guides explain the science shaping today’s experimental drugs.
What Is Genomics?
Genomics is the study of an organism's complete set of DNA, its genome, including how genes interact with each other and with the environment. It now shapes how new drugs are discovered.
What Is Precision Medicine?
Precision medicine tailors prevention and treatment to individual differences in genes, environment, and lifestyle. In drug development, it means matching a drug to the patients most likely to benefit, often using a genetic test.
How Does CRISPR Gene Editing Work?
CRISPR gene editing uses a guide RNA to lead a DNA-cutting enzyme, usually Cas9, to a precise location in the genome. The cell's repair of that cut can disable or correct a gene. The first CRISPR-based therapy was approved by the FDA in 2023.
What Are Genetic Mutations?
A genetic mutation, or variant, is a change in the DNA sequence. Some are inherited and present in every cell. Others arise during life in particular cells, as in cancer. Most have no effect, but some cause disease or change how a person responds to drugs.
What Is Proteomics?
Proteomics is the large-scale study of proteins: which proteins are present, how much of each, and how they change. Because most drugs act on proteins, proteomics is increasingly used to find drug targets and biomarkers.
What Is Whole Genome Sequencing?
Whole genome sequencing reads nearly all of a person's roughly 3 billion DNA base pairs in a single test. It finds more kinds of genetic variation than narrower tests and is increasingly used to diagnose rare diseases and to discover drug targets.
Approval odds, clearly labeled
Each development program on a drug profile shows how often comparable programs at the same stage went on to FDA approval, from industry-wide data for 2011–2020.
These are historical benchmarks, labeled as such, not predictions for any individual drug. We pair them with our sourced reading of each drug’s evidence.
Read the methodologyScientific perspective
Mechanism of action, trial design, efficacy, safety, and the quality of the evidence behind each claim.
Development perspective
Pipeline stage, upcoming milestones, development risks, and what the sponsor has disclosed, kept separate from our scientific conclusions.
Frequently asked questions
Where can I find clinical drug trial results?
Most trials of drugs regulated by the FDA must be registered on ClinicalTrials.gov, which also posts summary results for many completed trials. Full results usually appear in peer-reviewed journals, and for approved drugs the FDA publishes its own review documents in Drugs@FDA. Spectral Genomics links each result back to these original sources and labels whether it is peer-reviewed or company-reported.
What is an experimental medical drug?
An experimental, or investigational, drug is one that has not been approved for the use being studied. In the United States it can only be tested in people under an Investigational New Drug application with the FDA, typically through Phase 1, 2, and 3 clinical trials.
How likely is an experimental drug to be approved?
Historically, about 7.9% of drugs entering Phase 1 trials were eventually approved, according to an industry analysis of 2011–2020 programs. About 15% of drugs entering Phase 2 and about 52% of drugs reaching Phase 3 went on to approval. The odds vary widely by disease area and by how patients are selected.
What is drug pipeline tracking?
Drug pipeline tracking means following a drug or a company’s portfolio of drugs as it moves through development: trial starts and results, phase changes, regulatory designations, and FDA decisions. Spectral Genomics drug profiles track each program’s registered trials and FDA status with dates and sources, and Pipeline News collects the companies’ own announcements from SEC filings and press releases.
Is Spectral Genomics investment or medical advice?
No. Spectral Genomics provides independent information for education and research. Approval odds are statistical summaries of past development programs, not recommendations to buy or sell securities, and nothing on the site is medical advice.